Leo I Gordon

Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division

Scopus Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.

The novel expanded porphyrin, motexafin gadolinium, combined with [ ⁹⁰Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: Preclinical findings and results of a phase I trial

Andrew M. Evens; William G. Spies; Irene B. Helenowski; David Patton; Stewart Spies; Borko D. Jovanovic; Sarah Miyata; Elizabeth Hamilton; Daina Variakojis; Jun Chen; et al. (Profiled Authors: Leo I Gordon; Borko Jovanovic; Steven T Rosen; William G Spies; Stewart M Spies; Daina Variakojis; Jane Norma Winter)

Clinical Cancer Research. 2009;15(20):6462-6471.

Purpose: Therapeutic strategies to enhance the efficacy of radioimmunotherapy have not been explored. Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation. Experimental Design: We did preclinical studies examining motexafin gadolinium combined with rituximab and/or radiation in lymphoma cells. We subsequently completed a phase I clinical trial combining escalating doses of motexafin gadolinium concurrently with standard [ ⁹⁰Y]ibritumomab tiuxetan for patients with relapsed/refractory non-Hodgkin's lymphoma. Results: In HF1 lymphoma cells, motexafin gadolinium and rituximab resulted in synergistic cytotoxicity (combination index, 0.757) through a mitochondrial-mediated caspase-dependent pathway, whereas cell death in Ramos and SUDHL4 cells was additive. Motexafin gadolinium/rituximab combined with radiation (1-3 Gy) resulted in additive apoptosis. Twenty-eight of 30 patients were evaluable on the phase I clinical trial. Median age was 65 years (47-87 years), and histologies were marginal-zone (n = 1), mantle-cell (n = 3), diffuse large cell (n = 6), and follicular lymphoma (n = 18). Of all patients, 86% were rituximab refractory. Therapy was well tolerated, and no dose-limiting toxicity was seen. Overall response rate was 57% [complete remission (CR), 43%], with median time-to-treatment failure of 10 months (1-48+ months) and median duration-of-response of 17 months. Of note, all responses were documented at 4 weeks. Furthermore, in rituximab-refractory follicular lymphoma (n = 14), overall response rate was 86% (CR, 64%), with a median time-to-treatment failure of 14 months (2-48+ months). Conclusions: This represents the first report of a novel agent to be combined safely concurrently with radioimmunotherapy. Furthermore, tumor responses with [⁹⁰Y]ibritumomab tiuxetan/motexafin gadolinium were prompt with a high rate of CRs, especially in rituximab-refractory follicular lymphoma. © 2009 American Association for Cancer Research.

PMID: 19825958     PMCID: PMC2763343

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.